UOC
DNLI icon

UBS O'Connor’s Denali Therapeutics DNLI Stock Holding History

UBS O'Connor’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,039
Closed -$429K – 392
2024
Q4 		$429K Sell
21,039
-9,705
-32% -$248K 0.01% 295
2024
Q3 		$896K Sell
30,744
-773
-2% -$19.2K 0.02% 294
2024
Q2 		$732K Buy
31,517
+6,484
+26% +$124K 0.02% 337
2024
Q1 		$514K Sell
25,033
-9,431
-27% -$177K 0.01% 333
2023
Q4 		$740K Sell
34,464
-24,488
-42% -$485K 0.02% 306
2023
Q3 		$1.22M Buy
58,952
+10,000
+20% +$254K 0.02% 310
2023
Q2 		$1.44M Buy
+48,952
New +$1.38M 0.03% 343
2020
Q2 		– Sell
-37,200
Closed -$651K – 409
2020
Q1 		$651K Buy
+37,200
New +$776K 0.01% 250

Other funds holding DNLI

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return